$GCTK News

GlucoTrack Q1 EPS $(2.65) Up From $(40.20) YoY

Glucotrack Submits FDA Investigational Device Exemption For U.S. Clinical Study Of Fully Implantable Continuous Blood Glucose Monitoring System

Glucotrack Announces Publication Of Peer Reviewed Scientific Article In The Journal Of Diabetes Research On Long-Term Accuracy And Stability Of Fully Implantable CBGM System In In-Vivo Ovine Model

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

GlucoTrack Announces Publication Of Peer-Reviewed Study Supporting Implantable Blood Glucose Monitoring Tech

GlucoTrack Announces Publication Of Peer-Reviewed Study Supporting Implantable Blood Glucose Monitoring Tech

GlucoTrack shares are trading lower. The company reported its Q4 financial results.

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

GlucoTrack Q4 EPS $(3.97) Up From $(1.24 thousand) YoY

Glucotrack to File for FDA Exemption Based on 2025 Milestones

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

GlucoTrack shares are trading higher after the company announced that it will submit an investigational device exemption to the FDA for its novel continuous blood glucose monitoring technology, with a goal to file requisite documents with the FDA in Q2 2026.

Glucotrack Announces Preparations To Submit To The FDA For Clinical Trials Of Its Implantable Continuous Blood Glucose Monitoring Technology After Completing In-Human Studies In Brazil And Australia

Glucotrack To Submit IDE To FDA For Its Continuous Blood Glucose Monitoring Technology, With Goal To File Requisite Documents With FDA During Q2 Of 2026

Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit

Glucotrack Announces 3 New Patents to Monitor Blood Glucose

Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

The US Patent and Trademark Office has issued Patents For Glucotrack's Continuous Blood Glucose Monitoring Platform

Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

CORRECTION: Glucotrack Prices $4M Private Placement Of 1,033,591 Shares Of Common Stock And Warrants To Purchase Up To 2,067,182 Shares Of Common Stock At A Combined Price Of $3.87/Share